Floatz logo

Dfn-15

Osteoarthritis, Hip

PfizerPhase 4 / ApprovedDormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Osteoarthritis, Hip cohort.

Asset / SponsorPhaseRating
ROPIVACAINE
Poznan University of Medical Sciences
Phase 4BBB
ROPIVACAINE
Poznan University of Medical Sciences
Phase 4BBB
DEXAMETHASONE
Poznan University of Medical Sciences
Phase 4BBB
Remimazolam
Seoul National University Hospital
Phase 4BB
Intravenous Dexamethsone
Poznan University of Medical Sciences
Phase 4BB

View all 17 →

Same molecule, other indications

Dfn-15 is also rated in:

osteoarthritis, kneeDormant
BB
Indicative ·
69 / 100
View asset →
ArthritisDormant
BB
Indicative ·
68 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →